Literature DB >> 11401661

MACS-II: does coping enhance subjective control over psychotic symptoms?

M Bak1, F van der Spil, N Gunther, S Radstake, P Delespaul, J van Os.   

Abstract

OBJECTIVE: Associations between subjective experience of control and the use of self-initiated coping strategies were examined in patients with psychotic symptoms.
METHOD: Twenty-three patients were interviewed to assess (i) the subjective experience of distress with and control over symptoms and (ii) the coping strategies used.
RESULTS: There was a positive association between coping type and control (OR = 1.07, 95% CI: 1.03-1.12). Active coping strategies had the strongest association with experience of control (active problem-solving: OR = 1.41 95% CI: 1.18-1.68; active problem-avoiding: OR = 1.45 95% CI: 1.18-1.68). Symptomatic coping was negatively associated with control (OR = 0.40, 95% CI: 0.30-0.55), but was the most frequently used strategy. Depressive symptoms were associated with the highest number of coping strategies.
CONCLUSION: Coping strategies differ in the degree and direction of associated subjective control, and symptoms differ in the degree with which coping is mobilized. Assessment of coping strategies may be useful as a prelude to psychological therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11401661     DOI: 10.1034/j.1600-0447.2001.00325.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  2 in total

1.  Capturing coping with symptoms in people with a diagnosis of schizophrenia: introducing the MACS-24.

Authors:  Maarten Bak; Philippe Delespaul; Lydia Krabbendam; Karola Huistra; Wil Walraven; Jim van Os
Journal:  Int J Methods Psychiatr Res       Date:  2009       Impact factor: 4.035

2.  Subjective experience of cognitive failures as possible risk factor for negative symptoms of psychosis in the general population.

Authors:  Stefanie Pfeifer; Jim van Os; Manon Hanssen; Philippe Delespaul; Lydia Krabbendam
Journal:  Schizophr Bull       Date:  2008-02-21       Impact factor: 9.306

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.